A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response

Rheumatology (United Kingdom)

Volumn 52, Issue 7, 2013, Pages 1239-1244

  Masui, Yuri ^a   Asano, Yoshihide ^a   Shibata, Sayaka ^a   Noda, Shinji ^a   Akamata, Kaname ^a   Aozasa, Naohiko ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Sumida, Hayakazu ^a   Yanaba, Koichi ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a   Kadono, Takafumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Collagen; Interleukin 12; Matrix metalloproteinase 1; Systemic sclerosis; Visfatin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; BLOOD SAMPLING; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SKINFOLD; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

COLLAGEN; INTERLEUKIN-12; MATRIX METALLOPROTEINASE 1; SYSTEMIC SCLEROSIS; VISFATIN;

CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-12; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, DIFFUSE; SKIN; TH1 CELLS;

EID: 84879806467     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket010     Document Type: Article

References (20)

1. Masui Y, Asano Y, Shibata S et al. Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 2012;26:354-60.
2. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
3. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.
4. Huang JF, Huang CF, Yu ML et al. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection. J Gastroenterol Hepatol 2011;26:530-5.
5. Kukla M, Ciupiń ska-Kajor M, Kajor M et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010;61:147-53.
6. Yu XY, Qiao SB, Guan HS et al. Effects of visfatin on proliferation and collagen synthesis in rat cardiac fibroblasts. Horm Metab Res 2010;42:507-13.
7. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113: 1318-27.
8. Bao JP, Chen WP, Wu LD. Visfatin: a potential therapeutic target for rheumatoid arthritis. J Int Med Res 2009;37: 1655-61.
9. Ozgen M, Koca SS, Aksoy K et al. Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol 2011;30:757-63.
10. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
12. Asano Y, Stawski L, Hant F et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010;176: 1983-98.
13. Takeda K, Hatamochi A, Ueki H et al. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994; 103:359-63.
14. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 1997; 289:567-72.
15. Matsushita T, Hasegawa M, Hamaguchi Y et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006;33:275-84.
16. Otero M, Lago R, Gomez R et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201.
17. Brentano F, Schorr O, Ospelt C et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56: 2829-39.
18. Nowell MA, Richards PJ, Fielding CA et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006;54: 2084-95.
19. Busso N, Karababa M, Nobile M et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 2008;3:e2267.
20. Yuan C, Liang NL, Liu XJ et al. [Effect of visfatin on the expression of basic fibroblast growth factor in rat hepatic stellate cells]. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:617-20.